Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 6

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 6
---
 “designed,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” and “would,” as well as similar expressions which predict or indicate future events and trends or which do not relate to historical matters, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. For example, we may use forward-looking statements when addressing topics such as:

| • |     | our anticipated expenditures, including research and development, and general and administrative expenses; |

| • |     | our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of 
 such arrangements, including license agreements;                                                                |

| • |     | U.S. Food and Drug Administration and European Medicines Agency approvals and interactions and government 
 regulation;                                                                                               |

| • |     | the potential size of the market for our product candidates; |

| • |     | the timing or likelihood of regulatory filings and our ability to obtain and maintain regulatory approvals; |

| • |     | any future commercialization of our product candidates and laboratory tests; |

| • |     | our ability to enroll patients in our clinical trials; |

| • |     | our ability and the potential to successfully manufacture and supply our product candidates or laboratory tests 
 for clinical trials and for commercial use;                                                                     |

| • |     | our estimates regarding the potential market size and market opportunity for our product candidates and 
 laboratory tests;                                                                                       |

| • |     | our research and development efforts; |

| • |     | the timing of the initiation, progress, and expected results of our nonclinical studies, our pre-clinical and clinical trials, and our research and development programs; |

| • |     | our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical 
 trials;                                                                                                     |

| • |     | results from our pre-clinical and clinical studies and the implications     
 of such results regarding the efficacy or safety of our product candidates; |

| • |     | the safety profile, pathways, and efficacy of our product candidates and formulations; |

| • |     | the anticipated advantages of our product candidates and laboratory tests over other products available in the 
 market and being developed;                                                                                    |

| • |     | the populations that will most benefit from our product candidates and indications that will be